Page 138 - 2019年9月第30卷第18期

[ 6 ] SADANANDAM A，LYSSIOTIS CA，HOMICSKO K， EpCAM aptamer-siRNA chimera targets and regress epi-
et al. A colorectal cancer classification system that associ- thelial cancer[J]. PLoS One，2015. DOI：10.1371/journal.
ates cellular phenotype and responses to therapy[J]. Nat pone.0132407.
Med，2013，19（5）：619-625. [21] XIE X，LI F，ZHANG H，et al. EpCAM aptamer-function-
[ 7 ] LEE JY. Hyaluronan：a multifunctional，megadalton，stea- alized mesoporous silica nanoparticles for efficient colon
lth molecule[J]. Curr Opin Cell Biol，2000，12（5）：581- cancer cell-targeted drug delivery[J]. Europ J Pharm Sci，
586. 2016. DOI：10.1016/j.ejps.2015.12.014.
[ 8 ] ZÖLLER M. CD44：can a cancer-initiating cell profit from [22] RAY P，WHITE RR. Aptamers for targeted drug delivery
an abundantly expressed molecule? [J]. Nat Rev Cancer， [J]. Pharmaceuticals，2010，3（6）：1761-1778.
2011，11（4）：254-267. [23] FERREIRA CSM，CHEUNG MC，MISSAILIDIS S，et al.
[ 9 ] TOOLE BP. Hyaluronan in morphogenesis[J]. Semin Cell Phototoxic aptamers selectively enter and kill epithelial
Dev Biol，2001，12（2）：79-87. cancer cells[J]. Nucleic Acids Res，2009，37（3）：866-876.
[10] ZHU C，ZHANG H，LI W，et al. Suppress orthotopic co- [24] 张磊，鲁莹，钟延强. Affibody分子：一类具有高度亲和力
lon cancer and its through exact targeting and highly se- 的新配体[J]. 国际药学研究杂志，2012，39（2）：127-131.
lective drug release by a smart nanomicelle[J]. Biomateri- [25] SPANO JP. Impact of EGFR expression on colorectal can-
als，2018. DOI：10.1016/j.biomaterials.2018.0.1.043. cer patient prognosis and survival[J]. Ann Oncol，2005，16
[11] LIU K，WANG ZQ，WANG SJ，et al. Hyaluronic acid- （1）：102-108.
tagged silica nanoparticles in colon cancer therapy：thera- [26] PORĘBSKA I，HARŁOZIŃSKA A，BOJAROWSKI T.
peutic efficacy evaluation[J]. Int J Nanomed，2015，10 Expression of the tyrosine kinase activity growth factor re-
（1）：6445-6454. ceptors（EGFR，ERB B2，ERB B3）in colorectal adenocar-
[12] ZHANG M，XU C，WEN L，et al. A hyaluronidase respon- cinomas and adenomas[J]. Tumor Biol，2000，21（2）：
sive nanoparticle-based drug delivery system for targeting 105-115.
colon cancer cells[J]. Cancer Res，2016，76（24）：7208- [27] LIANG K，ANG KK，MILAS L，et al. The epidermal
7218. growth factor receptor mediates radioresistance[J]. Int J
[13] ANTONY AC. Folate receptors[J]. Annu Rev Nutr，1996， Radiat Oncol Biol Phys，2003，57（1）：246-254.
16（16）：501-521. [28] SARA HS，DIANA S，JOHAN L，et al. The effect of a di-
[14] SIU MKY，KONG DSH，YAN CH，et al. Paradoxical im- meric Affibody molecule（ZEGFR：1907 ）2 targeting EGFR in
pact of two folate receptors，FR-α and RFC，in ovarian combination with radiation in colon cancer cell lines[J].
cancer：effect on cell proliferation，invasion and clinical Int J Oncol，2012，40（1）：176-184.
outcome[J]. PLoS One，2012. DOI：10.1371/journal.pone. [29] GOVERNATORE MD，HAMBLIN MR，PICCININI EE，
0047201. et al. Targeted photodestruction of human colon cancer
[15] LUO M，LIANG X，LUO ST，et al. Folate-modified lipo- cells using charged 17.1A chlorin（e6）immunoconjugates
plexes delivering the interleukin-12 gene for targeting co- [J]. Br J Cancer，2000，82（1）：56-64.
lon cancer immunogene therapy[J]. J Biomed Nanotech- [30] KONING GA，KAMPS JAAM，SCHERPHOF GL. Effi-
nol，2015，11（11）：2011-2023. cient intracellular delivery of 5-fluorodeoxyuridine into
[16] LEHR CM. Lectin-mediated drug delivery：the second colon cancer cells by targeted immunoliposomes[J]. Can-
generation of bioadhesives[J]. J Control Release，2000，65 cer Detect Prev，2002，26（4）：299-307.
（1/2）：19-29. [31] CHO YS，YOON TJ，JANG ES，et al. Cetuximab-conju-
[17] WANG C，HO PC，LIM LY. Wheat germ agglutinin-conju- gated magneto-fluorescent silica nanoparticles for in vivo
gated PLGA nanoparticles for enhanced intracellular deliv- colon cancer targeting and imaging[J]. Cancer Letters，
ery of paclitaxel to colon cancer cells[J]. Inter J Pharm， 2010，299（1）：63-71.
2010，400（1/2）：201-210. [32] THOMAS SM，GRANDIS JR. Pharmacokinetic and phar-
[18] PEI X，ZHANG J，LIU J. Clinical applications of nucleic macodynamic properties of EGFR inhibitors under clini-
acid aptamers in cancer[J]. Mol Clin Oncol，2014，2（3）： cal investigation[J]. Cancer Treat Rev，2004，30（3）：255-
341-348. 268.
[19] ZHOU B，WANG B. Pegaptanib for the treatment of age- [33] GENE LB，AISHA ND，DRAZEN R. Targeting a c-Myc
related macular degeneration[J]. Exp Eye Res，2006，83 inhibitory polypeptide to specific intracellular compart-
（3）：615-619. ments using cell penetrating peptides[J]. J Control Re-
[20] SUBRAMANIAN N，KANWAR JR，KANWAR RK，et al. lease，2009，135（1）：2-10.

中国药房 2019年第30卷第18期 China Pharmacy 2019 Vol. 30 No. 18 ·2581 ·